Format

Send to

Choose Destination
Science. 2015 Jul 17;349(6245):320-4. doi: 10.1126/science.aab3886. Epub 2015 Jul 2.

Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys.

Author information

1
Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA. Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, MA 02139, USA. dbarouch@bidmc.harvard.edu.
2
Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, MA 02139, USA.
3
Thayer School of Engineering at Dartmouth, Hanover, NH 03755, USA.
4
Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
5
University of Massachusetts Medical School, Worcester, MA 01605, USA.
6
New England Primate Research Center, Southborough, MA 01772, USA.
7
Bioqual, Rockville, MD 20852, USA.
8
Children's Hospital, Boston, MA 02115, USA.
9
JPT Peptide Technologies GmbH, 12489 Berlin, Germany.
10
AIDS and Cancer Virus Program, Leidos Biomedical Research, Frederick National Laboratory, Frederick, MD 21702, USA.
11
Washington University School of Medicine, St. Louis, MO 63110, USA.
12
GSK Vaccines, 1330 Rixensart, Belgium.
13
Janssen Infectious Diseases and Vaccines (formerly Crucell), 2301 Leiden, Netherlands.

Abstract

Preclinical studies of viral vector-based HIV-1 vaccine candidates have previously shown partial protection against neutralization-resistant virus challenges in rhesus monkeys. In this study, we evaluated the protective efficacy of adenovirus serotype 26 (Ad26) vector priming followed by purified envelope (Env) glycoprotein boosting. Rhesus monkeys primed with Ad26 vectors expressing SIVsmE543 Env, Gag, and Pol and boosted with AS01B-adjuvanted SIVmac32H Env gp140 demonstrated complete protection in 50% of vaccinated animals against a series of repeated, heterologous, intrarectal SIVmac251 challenges that infected all controls. Protective efficacy correlated with the functionality of Env-specific antibody responses. Comparable protection was also observed with a similar Ad/Env vaccine against repeated, heterologous, intrarectal SHIV-SF162P3 challenges. These data demonstrate robust protection by Ad/Env vaccines against acquisition of neutralization-resistant virus challenges in rhesus monkeys.

PMID:
26138104
PMCID:
PMC4653134
DOI:
10.1126/science.aab3886
[Indexed for MEDLINE]
Free PMC Article

Publication types, MeSH terms, Substances, Grant support

Publication types

MeSH terms

Substances

Grant support

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center